EUCTR2011-002545-35-DE进行中（未招募）1 期
A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 or pazopanib in Melanoma
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 138
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Aged = 18 years
- •2. Able to provide evidence from an accredited laboratory of wt BRAF status for their melanoma, or ascertainment of wt BRAF status from a sample of melanoma provided for mutational analysis in Oxford (phase 2 part only).
- •3. Unresectable stage 3 or 4, histologically proven cutaneous or unknown primary melanoma
- •4. Measurable disease as defined by RECIST 1.1 (phase 2 part only).
- •5. ECOG performance score of 0 or 1.
- •6. Life expectancy of at least 12 weeks.
- •7. Adequate cardiac function (NYHA 0-1), and LVEF within normal limits on echocardiogram.
- •8. The patient is willing to give consent to the main study and able to comply with the protocol for the duration of the study, including scheduled follow-up visits and examinations.
- •9. Adequate haematological, hepatic and renal function.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Any systemic anti-cancer therapy (including participation in other clinical trials) within 28 days prior to Day 1 (42 days prior for ipilimumab).
- •2. Any radiotherapy within 14 days prior to Day 1.
- •3. Prior taxane or BRAF or MEK inhibitors for metastatic melanoma.
- •4. Any unresolved toxicity from prior anti-cancer therapy that is greater than CTCAE grade 2.
- •5. Pregnancy or breastfeeding women. Female patients must have a negative urinary or serum pregnancy test or have evidence of post-menopausal status (defined as absence of menstruation for > 12 months, bilateral oophrectomy or hysterectomy).
- •6. Grade =2 peripheral neuropathy at study entry.
- •7. Patients of reproductive potential who are not willing to use adequate contraceptive measures for the duration of the study (both male and female patients)
- •8. Known severe hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor EL and ethanol
- •9. Ocular or mucosal malignant melanoma
- •10. Another active malignancy within the past three years.
- •11. Evidence of brain metastases, unless surgically resected/stereotactic radiosurgery treated brain metastasis with no evidence of relapse on cerebral MRI, or treated brain metastasis and stable off treatment, including steroids, for 3 months.
- •12. Clinically significant and uncontrolled major medical condition(s), such as active infection, bleeding diathesis or increased risk of bleeding and gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
- •13. Poorly controlled hypertension
- •14. Major surgery or trauma within 28 days prior to first dose of treatment
- •15. Patients who are known to be serologically positive for Hepatitis B, Hepatitis C or HIV.
- •16. Inability to swallow tablets, refractory nausea and vomiting, chronic gastrointestinal diseases (eg, inflammatory bowel disease) or significant bowel resection that would preclude adequate absorption of GSK1120212 or pazopanib
- •17. Ocular disease predisposing to central serous retinopathy and/or retinal vein occlusion, including increased intra-ocular pressure, glaucoma, uncontrolled hypertension or uncontrolled diabetes.
- •18. Corrected QT interval (QTc) > 480 msecs or recent history of ischaemic heart disease/peripheral vascular disease/cerebrovascular disease
研究者
相似试验
进行中（未招募）
1 期
A randomised phase 2 study of paclitaxel with or without GSK1120212 in advanced wt BRAF melanoma - Paclitaxel +/- GSK1120212 in MelanomaEUCTR2011-002545-35-GBniversity of Oxford111
进行中（未招募）
不适用
Breast cancer studyHer-2 negative metastatic or locally advanced inoperable breast cancerMedDRA version: 17.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-018025-73-DEGMIHO mbH
已完成
2 期
A phase II study of weekly paclitaxel in patients with advanced or recurrent esophageal cancer who had previously received docetaxel-containing chemotherapyAdvanced or recurrent esophageal cancerJPRN-UMIN000019230niversity of Miyazaki Hospital25
招募中
2 期
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric CancerAdvanced or recurrent gastric cancer previously treated with S-1JPRN-UMIN000008632Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine35
已完成
2 期
A randomized phase II study of paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV non-squamous-non-small cell lung cancer: NVALT1210029107non-small cell lung cancerNL-OMON36516Stichting NVALT studies222